Drug
Zilovertamab Vedotin
Zilovertamab Vedotin: highest development phase Phase 3, developed by Merck. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Zilovertamab vedotin NCT06717347 | Phase 3 | Diffuse Large B-Cell Lymphoma |
| Zilovertamab vedotin NCT05144841 | Phase 2 | Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
| Zilovertamab vedotin NCT05562830 | Phase 1/2 | Urothelial Carcinoma |
Latest
Follow Zilovertamab Vedotin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.